Deutsche Bank initiated coverage on shares of Mirati Therapeutics (NASDAQ:MRTX) in a report published on Thursday, BenzingaRatingsTable reports. The firm issued a hold rating and a $86.00 target price on the biotechnology company’s stock.
Other equities analysts have also issued reports about the stock. Barclays restated an overweight rating and set a GBX 3,150 ($41.16) price target on shares of in a research report on Wednesday, June 5th. Credit Suisse Group set a $155.00 price target on shares of Allergan and gave the stock a hold rating in a research report on Monday, March 25th. SunTrust Banks boosted their price target on shares of Mirati Therapeutics to $120.00 and gave the stock a buy rating in a research report on Tuesday, June 4th. HC Wainwright restated a buy rating on shares of Zomedica Pharmaceuticals in a research report on Wednesday, June 5th. Finally, Guggenheim lowered shares of Mirati Therapeutics from a buy rating to a neutral rating and set a $95.56 price target on the stock. in a research report on Friday, June 7th. One analyst has rated the stock with a sell rating, five have given a hold rating and twelve have issued a buy rating to the company. The company has a consensus rating of Buy and a consensus price target of $94.70.
MRTX opened at $106.00 on Thursday. Mirati Therapeutics has a twelve month low of $28.50 and a twelve month high of $109.64. The stock’s 50-day simple moving average is $100.04.
Mirati Therapeutics (NASDAQ:MRTX) last posted its quarterly earnings results on Monday, April 29th. The biotechnology company reported ($1.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.20). The company had revenue of $1.24 million for the quarter. Analysts anticipate that Mirati Therapeutics will post -4.97 EPS for the current fiscal year.
In other Mirati Therapeutics news, Director Michael G. Grey sold 5,760 shares of Mirati Therapeutics stock in a transaction dated Monday, May 13th. The shares were sold at an average price of $65.30, for a total transaction of $376,128.00. Following the transaction, the director now directly owns 7,100 shares of the company’s stock, valued at $463,630. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Boxer Capital, Llc sold 725,008 shares of Mirati Therapeutics stock in a transaction dated Wednesday, July 17th. The stock was sold at an average price of $98.30, for a total transaction of $71,268,286.40. The disclosure for this sale can be found here. Insiders have sold 741,268 shares of company stock worth $72,432,514 over the last ninety days. 4.86% of the stock is owned by insiders.
Institutional investors have recently added to or reduced their stakes in the company. RTW Investments LP purchased a new stake in shares of Mirati Therapeutics in the 4th quarter valued at approximately $1,644,000. United Services Automobile Association raised its stake in shares of Mirati Therapeutics by 2.5% in the 4th quarter. United Services Automobile Association now owns 7,222 shares of the biotechnology company’s stock valued at $306,000 after acquiring an additional 173 shares during the period. JGP Global Gestao de Recursos Ltda. purchased a new stake in shares of Mirati Therapeutics in the 1st quarter valued at approximately $242,000. Handelsbanken Fonder AB purchased a new stake in shares of Mirati Therapeutics in the 1st quarter valued at approximately $2,932,000. Finally, Pictet Asset Management Ltd. raised its stake in shares of Mirati Therapeutics by 0.9% in the 1st quarter. Pictet Asset Management Ltd. now owns 235,975 shares of the biotechnology company’s stock valued at $17,297,000 after acquiring an additional 2,141 shares during the period.
Mirati Therapeutics Company Profile
Mirati Therapeutics, Inc, a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company is involved in developing sitravatinib, a spectrum-selective kinase inhibitor, which is in Phase II clinical for the treatment of non-small cell lung cancer (NCSLC); and in Phase Ib clinical trial to treat NCSLC patients with Casitas B-lineage Lymphoma genetic alterations, as well as KRAS G12C inhibitor program for NSCLC adenocarcinoma patients, colorectal cancer patients, and other cancers.
Further Reading: What are gap-up stocks?
Receive News & Ratings for Mirati Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.